Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases

S. H. Cheon, SunYoung Rha, H. C. Jeung, C. K. Im, S. H. Kim, H. R. Kim, J. B. Ahn, J. K. Roh, S. H. Noh, Hyuncheol Chung

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Background: The benefit of surgical resection of liver metastases from gastric cancer has not been well established. The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer. Methods: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery. Results: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years. Of the 41 patients, 22 had complete resection and 19 had palliative resection. Between the curative and palliative resections, survival rates after curative intent were not different. The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival. Conclusions: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved. Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

Original languageEnglish
Pages (from-to)1146-1153
Number of pages8
JournalAnnals of Oncology
Volume19
Issue number6
DOIs
Publication statusPublished - 2008 Jun 1

Fingerprint

Stomach Neoplasms
Stomach
Neoplasm Metastasis
Survival
Liver
Adenocarcinoma
Survival Rate
Health

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Cheon, S. H. ; Rha, SunYoung ; Jeung, H. C. ; Im, C. K. ; Kim, S. H. ; Kim, H. R. ; Ahn, J. B. ; Roh, J. K. ; Noh, S. H. ; Chung, Hyuncheol. / Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. In: Annals of Oncology. 2008 ; Vol. 19, No. 6. pp. 1146-1153.
@article{abf3c1c1f28f410285e0f7b9555b5803,
title = "Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases",
abstract = "Background: The benefit of surgical resection of liver metastases from gastric cancer has not been well established. The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer. Methods: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery. Results: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3{\%}, 31.7{\%}, and 20.8{\%}, respectively, and three patients survived >7 years. Of the 41 patients, 22 had complete resection and 19 had palliative resection. Between the curative and palliative resections, survival rates after curative intent were not different. The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival. Conclusions: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved. Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.",
author = "Cheon, {S. H.} and SunYoung Rha and Jeung, {H. C.} and Im, {C. K.} and Kim, {S. H.} and Kim, {H. R.} and Ahn, {J. B.} and Roh, {J. K.} and Noh, {S. H.} and Hyuncheol Chung",
year = "2008",
month = "6",
day = "1",
doi = "10.1093/annonc/mdn026",
language = "English",
volume = "19",
pages = "1146--1153",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "6",

}

Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. / Cheon, S. H.; Rha, SunYoung; Jeung, H. C.; Im, C. K.; Kim, S. H.; Kim, H. R.; Ahn, J. B.; Roh, J. K.; Noh, S. H.; Chung, Hyuncheol.

In: Annals of Oncology, Vol. 19, No. 6, 01.06.2008, p. 1146-1153.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases

AU - Cheon, S. H.

AU - Rha, SunYoung

AU - Jeung, H. C.

AU - Im, C. K.

AU - Kim, S. H.

AU - Kim, H. R.

AU - Ahn, J. B.

AU - Roh, J. K.

AU - Noh, S. H.

AU - Chung, Hyuncheol

PY - 2008/6/1

Y1 - 2008/6/1

N2 - Background: The benefit of surgical resection of liver metastases from gastric cancer has not been well established. The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer. Methods: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery. Results: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years. Of the 41 patients, 22 had complete resection and 19 had palliative resection. Between the curative and palliative resections, survival rates after curative intent were not different. The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival. Conclusions: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved. Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

AB - Background: The benefit of surgical resection of liver metastases from gastric cancer has not been well established. The aim of this study was to evaluate the rationale for hepatic resection in patients with hepatic metastases from gastric cancer. Methods: Among 10 259 patients diagnosed with gastric adenocarcinoma in the Yonsei University Health System from 1995 to 2005, we reviewed the records of 58 patients with liver-only metastases from gastric cancer who underwent gastric resection regardless of hepatic surgery. Results: The overall 1-year, 3-year, and 5-year survival rates of 41 patients who underwent hepatic resection with curative intent were 75.3%, 31.7%, and 20.8%, respectively, and three patients survived >7 years. Of the 41 patients, 22 had complete resection and 19 had palliative resection. Between the curative and palliative resections, survival rates after curative intent were not different. The number of liver metastasis (solitary or multiple) was a marginally significant prognostic factor for survival. Conclusions: Surgery for liver metastases arising from gastric adenocarcinoma is reasonable if complete resection seems feasible after careful preoperative staging, even if complete resection is not actually achieved. Hepatic resection should be considered as an option for gastric cancer patients with hepatic metastases.

UR - http://www.scopus.com/inward/record.url?scp=44849143053&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44849143053&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdn026

DO - 10.1093/annonc/mdn026

M3 - Article

C2 - 18304963

AN - SCOPUS:44849143053

VL - 19

SP - 1146

EP - 1153

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -